Newark, New Castle, USA, May 22, 2023 (GLOBE NEWSWIRE) -- The market analysis of the global nicotinic antagonists market was conducted by Growth Plus Reports in 2022. The market is expected to hit a revenue CAGR of 3.75% by 2031.
Analysis of the global market for nicotinic antagonists indicates that during the forecast period, revenue share is likely to increase significantly. A family of medications called nicotinic antagonists often referred to as nicotinic receptor antagonists or nicotinic blockers, prevents the body's nicotinic acetylcholine receptors from functioning.
Key Takeaways:
- The main use of nicotinic antagonists is the management of hypertension.
- Nicotinic agonists are used to treat Alzheimer's disease.
- The rising demand for pain and addiction treatment is rapidly increasing market revenue growth.
Get a Free Sample Research Report: https://www.growthplusreports.com/inquiry/request-sample/nicotinic-antagonists-market/8998
Nicotinic Antagonists Market Scope
| Report Attribute | Details |
| CAGR | 3.75% |
| Base Year for Estimation | 2022 |
| Forecast Period | 2023 to 2031 |
| Historical Year | 2021 |
| Segments Covered | Drug Class, Distribution Channel, and Region |
| Regional Scope | North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
Recent Development in the Nicotinic Antagonists Market:
- In March 2023, the phase 2 results of CVN424, a novel, selective antagonist of the nicotinic Alpha6 receptor, provided encouraging data updates on new therapeutic strategies for Parkinson's disease.
Competitive Landscape
A list of the prominent players operating in the global market for nicotinic antagonists includes:
- Glaxo SmithKline plc
- Organon & Co.
- Hikma Labs Inc.
- Merck & Co., Inc.
- Cipla Ltd.
Market Drivers and Restraints:
The global nicotinic antagonists market revenue is driven by the rising cases of hypertension and Alzheimer's disease and rising demand for their related medications. Furthermore, the increasing number of populations inclining toward addiction leads to the demand for addiction treatment medication. Therefore, this growing demand for addiction treatment as well as pain medications is bolstering the market revenue growth.
However, due to unawareness among people about the benefits of nicotinic antagonists and stringent regulations imposed by regulatory bodies, the nicotinic antagonists' market revenue growth is expected to be restrained.
Market Segmentation:
- Based on drug class, the global nicotinic antagonists market is segmented into nondepolarizing NMJ blockers, depolarizing NMJ blockers, ganglionic blockers, and others.
- Based on distribution channels, the global nicotinic antagonists market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/nicotinic-antagonists-market/8998
Segmentation By Drug Class
Based on the drug class, the nondepolarizing NMJ blockers segment dominates the global nicotinic antagonists market with the largest revenue share. This large revenue share is attributed to advances in anesthesia and critical care medicine, as well as an increase in the number of surgical operations needing neuromuscular blockade.
Regional Growth Dynamics
Based on the region, North America, with the largest revenue share, dominates the global nicotinic antagonists market. The expansion of North America's revenue is being attributed to rising rates of hypertension, surgery, and endotracheal intubation, as well as rising levels of R&D and the existence of important market participants here.
Report Coverage
Growth Plus Reports carried out extensive market research on the nicotinic antagonists market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2021
- Base Year – 2022
- Forecast Years – 2023 to 2031
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2022)
- Regulatory Landscape
- Reimbursement Scenario
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL NICOTINIC ANTAGONISTS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
- Nondepolarizing NMJ Blockers
- Depolarizing NMJ Blocker
- Ganglionic Blockers
- Others
- GLOBAL NICOTINIC ANTAGONISTS MARKET - ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
NICOTINIC ANTAGONISTS MARKET TOC
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8998
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market.
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse more latest healthcare reports:
Wearable Cardioverter Defibrillator Market by Indication (Peripartum Cardiomyopathy, Congenital Heart Disease), End User (Home Care Settings, Hospitals) – Global Outlook & Forecast 2023-2031
Inflammatory Diseases Treatment Market by Disease Indication (Inflammatory Bowel Disease, Asthma & COPD), Treatment (Nonsteroidal Anti-inflammatory Drugs, Corticosteroids), End User (Hospitals Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Synoptophore Market by Product Type (Manual and Automatic), Application (Therapeutics and Diagnostics), End User (Hospitals, Clinics) – Global Outlook & Forecast 2023-2031
Sympathomimetics in Glaucoma Therapy Market by Drug (Dipivefrin, Apraclonidine), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
Erysipeloid Treatment Market by Drug Type (Erythromycin, Penicillin), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
